<?xml version="1.0" encoding="UTF-8"?>
<ref id="B93-pharmaceuticals-13-00096">
 <label>93.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Cantini</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Nannini</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Niccoli</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Petrone</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Ippolito</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Goletti</surname>
    <given-names>D.</given-names>
   </name>
  </person-group>
  <article-title>Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted biologics</article-title>
  <source>Mediators Inflamm.</source>
  <year>2017</year>
  <volume>2017</volume>
  <fpage>8909834</fpage>
  <pub-id pub-id-type="doi">10.1155/2017/8909834</pub-id>
  <pub-id pub-id-type="pmid">28659665</pub-id>
 </element-citation>
</ref>
